More pain ahead for Glenmark Pharma? 3 reasons why Nomura sees 25% downside after licencing deal for cancer drug
- Posted on September 25, 2025
- By Financial Express
- 1 Views
More pain ahead for Glenmark Pharma? 3 reasons why Nomura sees 25% downside after licencing deal for cancer drug
Discover why Nomura predicts a 25% downside for Glenmark Pharma despite its new cancer drug deal—read their analysis before investing!
